Comparative Pharmacology
Head-to-head clinical analysis: PRAZOSIN HYDROCHLORIDE versus UROXATRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRAZOSIN HYDROCHLORIDE versus UROXATRAL.
PRAZOSIN HYDROCHLORIDE vs UROXATRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prazosin is a quinazoline derivative that acts as a selective, competitive antagonist at postsynaptic alpha-1 adrenergic receptors. It blocks the binding of norepinephrine, thereby inhibiting vasoconstriction and reducing peripheral vascular resistance, leading to decreased blood pressure. It also relaxes smooth muscle in the prostate and bladder neck, improving urine flow. Additionally, it may block alpha-1 receptors in the central nervous system, reducing sympathetic outflow and ameliorating nightmare-related symptoms in PTSD.
Selective antagonist of postsynaptic alpha1A-adrenoceptors in the prostate, bladder base, and prostatic urethra, leading to relaxation of smooth muscle and improved urinary flow.
1 mg orally 2-3 times daily, titrated up to 20 mg/day in divided doses for hypertension; for benign prostatic hyperplasia, 0.5-1 mg orally twice daily.
10 mg orally once daily, immediately after the same meal each day.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours. However, antihypertensive effect persists for up to 24 hours due to prolonged receptor binding, allowing once-daily dosing.
The terminal elimination half-life is approximately 5 to 9 hours in healthy young subjects, and 6 to 10 hours in elderly patients. This supports once-daily dosing, with steady state achieved after 3-5 days.
Primarily hepatic metabolism (demethylation and conjugation); <10% unchanged in urine; 90% eliminated via bile/feces.
After oral administration, approximately 11% of the dose is excreted unchanged in urine, while 49% is excreted as metabolites in urine and 22% in feces. Overall, renal elimination accounts for about 60% of total clearance.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker